Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 51

1.

The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis.

Wu T, Duan X, Cao CX, Peng CD, Bu SY, Wang KJ.

Urol Int. 2014 Aug 7. [Epub ahead of print]

PMID:
25115445
[PubMed - as supplied by publisher]
2.

Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.

Medhi B, Mittal N, Bansal D, Prakash A, Sarangi SC, Nirthi B.

Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53. Review.

PMID:
24968572
[PubMed - indexed for MEDLINE]
3.

Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z.

Eur Urol. 2014 Apr;65(4):755-65. doi: 10.1016/j.eururo.2013.11.010. Epub 2013 Nov 18. Review.

PMID:
24275310
[PubMed - indexed for MEDLINE]
4.

What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?

Caremel R, Loutochin O, Corcos J.

Int Urogynecol J. 2014 Feb;25(2):165-70. doi: 10.1007/s00192-013-2161-4. Epub 2013 Aug 7.

PMID:
23922008
[PubMed - in process]
5.

Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.

Bridgeman MB, Friia NJ, Taft C, Shah M.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):1029-38. doi: 10.1345/aph.1S054. Epub 2013 Jun 11. Review.

PMID:
23757386
[PubMed - indexed for MEDLINE]
6.

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE.

Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21.

PMID:
23692526
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Imidafenacin for the treatment of overactive bladder.

Leone Roberti Maggiore U, Scala C, Venturini PL, Ferrero S.

Expert Opin Pharmacother. 2013 Jul;14(10):1383-97. doi: 10.1517/14656566.2013.796930. Epub 2013 May 6. Review. Erratum in: Expert Opin Pharmacother. 2014 Feb;15(2):301.

PMID:
23641864
[PubMed - indexed for MEDLINE]
8.

[Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis].

Xu C, Jiang XZ, Zhang NZ, Zhao HF, Xu ZS.

Zhonghua Yi Xue Za Zhi. 2012 Dec 25;92(48):3398-402. Chinese.

PMID:
23327698
[PubMed - indexed for MEDLINE]
9.

Treatments for overactive bladder: focus on pharmacotherapy.

Geoffrion R.

J Obstet Gynaecol Can. 2012 Nov;34(11):1092-101.

PMID:
23231848
[PubMed - in process]
10.

Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review.

Moossdorff-Steinhauser HF, Berghmans B.

Neurourol Urodyn. 2013 Mar;32(3):206-14. doi: 10.1002/nau.22296. Epub 2012 Aug 20. Review.

PMID:
22907807
[PubMed - indexed for MEDLINE]
11.

Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.

Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, Venturini PL, Ferrero S.

Expert Opin Drug Metab Toxicol. 2012 Nov;8(11):1387-408. doi: 10.1517/17425255.2012.714365. Epub 2012 Aug 8. Review.

PMID:
22871042
[PubMed - indexed for MEDLINE]
12.

Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.

Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL.

Ann Intern Med. 2012 Jun 19;156(12):861-74, W301-10. doi: 10.7326/0003-4819-156-12-201206190-00436. Review.

PMID:
22711079
[PubMed - indexed for MEDLINE]
13.

Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness [Internet].

Shamliyan T, Wyman J, Kane RL.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr.

PMID:
22624162
[PubMed]
Books & Documents
14.

Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety.

Dell'Utri C, Digesu GA, Bhide A, Khullar V.

Int Urogynecol J. 2012 Oct;23(10):1337-44. Epub 2012 Mar 13. Review.

PMID:
22411206
[PubMed - indexed for MEDLINE]
15.

Solifenacin for overactive bladder: a systematic review and meta-analysis.

Luo D, Liu L, Han P, Wei Q, Shen H.

Int Urogynecol J. 2012 Aug;23(8):983-91. doi: 10.1007/s00192-011-1641-7. Epub 2012 Feb 7. Review.

PMID:
22310924
[PubMed - indexed for MEDLINE]
16.

Which anticholinergic drug for overactive bladder symptoms in adults.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.

PMID:
22258963
[PubMed - indexed for MEDLINE]
17.

Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?

Paquette A, Gou P, Tannenbaum C.

J Am Geriatr Soc. 2011 Jul;59(7):1332-9. doi: 10.1111/j.1532-5415.2011.03473.x. Epub 2011 Jun 30. Review.

PMID:
21718264
[PubMed - indexed for MEDLINE]
18.

Nocturnal enuresis.

Kiddoo D.

Clin Evid (Online). 2011 Jan 31;2011. pii: 0305.

PMID:
21477399
[PubMed - in process]
Free PMC Article
19.

Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.

Kessler TM, Bachmann LM, Minder C, Löhrer D, Umbehr M, Schünemann HJ, Kessels AG.

PLoS One. 2011 Feb 23;6(2):e16718. doi: 10.1371/journal.pone.0016718.

PMID:
21373193
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review.

Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z.

Int J Clin Pract. 2011 Apr;65(4):487-507. doi: 10.1111/j.1742-1241.2010.02611.x. Epub 2011 Jan 7. Review.

PMID:
21210910
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk